Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifeprunox in Bipolar Depression
NCT00134459Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2005
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar disorder (BD) comparing Bifeprunox with Placebo (2 arms). Primary endpoint: Superiority of bifeprunox to placebo at 8 weeks. Started Jun 2005; status: completed.
02
Drugs
bifeprunox
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00134459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00134459.